Langerhans cell histiocytosis: Old disease new treatment

QJM: An International Journal of Medicine

Volumn 104, Issue 2, 2011, Pages 89-96

  Ng Cheng Hin, B ^a   O'Hanlon Brown, C ^a   Alifrangis, C ^a   Waxman, J ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BLEOMYCIN; CHLORMETHINE; CLADRIBINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN; CYTARABINE; DOXORUBICIN; ETOPOSIDE; ETRETIN; IMMUNOGLOBULIN; INDOMETACIN; INTERFERON; ISOTRETINOIN; MERCAPTOPURINE; METHOTREXATE; PREDNISOLONE; PSORALEN; RETINOIC ACID; STEROID; TACROLIMUS; THALIDOMIDE; VINBLASTINE; VINCRISTINE;

BONE LESION; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL FEATURE; CURETTAGE; DIABETES INSIPIDUS; DISEASE CLASSIFICATION; DRUG MECHANISM; HISTIOCYTOSIS X; HUMAN; LANGERHANS CELL; LUNG CYST; LUNG DISEASE; LUNG TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; PUVA; RARE DISEASE; RASH; RETROPERITONEAL FIBROSIS; REVIEW; TREATMENT RESPONSE;

EID: 78751699868     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcq206     Document Type: Review

References (68)

1. Favara BE, Feller AC, Pauli M, Jaffe ES, Weiss LM, Arico M, et al. Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification working group of the Histiocyte Society. Med Pediatr Oncol 1997; 29:157-66.
2. Hanau D, Gothelf Y, Schmitt DA, Fabre M, Garaud JC, Gazit E, et al. Internalization by receptor-mediated endocytosis of T6 (CD1 "NA1/34") surface antigen in T6 positive human cord blood cells (Langerhans cell precursors?). Nouv Rev Fr Hematol 1987; 29:279-83.
3. Merad M, Manz MG, Karsunky H, Wagers A, Peters W, Charo I, et al. Langerhans cells renew in the skin throughout life under steady-state conditions. Nat Immunol 2002; 3:1135-41.
4. Nezelof C, Basset F, Rousseau MF. Histiocytosis X histogenetic arguments for a Langerhans cell origin. Biomedicine 1973; 18:365-71.
5. Baumgartner I, von Hochstetter A, Baumert B, Luetolf U, Follath F. Langerhans'-cell histiocytosis in adults. Med Pediatr Oncol 1997; 28:9-14.
6. Carstensen H, Ornvold K. The epidemiology of Langerhans cell histiocytosis in children in Denmark, 1975-89. Med Pediatr Oncol 1993; 21:387-8.
7. Salotti JA, Nanduri V, Pearce MS, Parker L, Lynn R, Windebank KP. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child 2009; 94:376-80.
8. Willman CL, Busque L, Griffith BB, Favara BE, McClain KL, Duncan MH, et al. Langerhans'-cell histiocytosis (histiocytosis X)-a clonal proliferative disease. N Engl J Med 1994; 331:154-60.
9. Yousem SA, Colby TV, Chen YY, Chen WG, Weiss LM. Pulmonary Langerhans' cell histiocytosis: molecular analysis of clonality. Am J Surg Pathol 2001; 25:630-6.
10. Glotzbecker MP, Carpentieri DF, Dormans JP. Langerhans cell histiocytosis: a primary viral infection of bone? Human herpes virus 6 latent protein detected in lymphocytes from tissue of children. J Pediatr Orthop 2004; 24:123-9.
11. Broadbent V, Gadner H. Current therapy for Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12:327-38.
12. Lau L, Krafchik B, Trebo MM, Weitzman S. Cutaneous Langerhans cell histiocytosis in children under one year. Pediatr Blood Cancer 2006; 46:66-71.
13. Hoeger PH, Nanduri VR, Harper JI, Atherton DA, Pritchard J. Long term follow up of topical mustine treatment for cutaneous Langerhans cell histiocytosis. Arch Dis Child 2000; 82:483-7.
14. Munn S, Chu AC. Langerhans cell histiocytosis of the skin. Hematol Oncol Clin North Am 1998; 12:269-86.
15. Treat JR, Suchin KR, James WD. Topical nitrogen mustard ointment with occlusion for Langerhans' cell histiocytosis of the scalp. J Dermatolog Treat 2003; 14:46-7.
16. Singh A, Prieto VG, Czelusta A, McClain KL, Duvic M. Adult Langerhans cell histiocytosis limited to the skin. Dermatology 2003; 207:157-61.
17. Chu T. Langerhans cell histiocytosis. Australas J Dermatol 2001; 42:237-42.
18. Fernandez-Latorre F, Menor-Serrano F, Alonso-Charterina S, Arenas-Jimenez J. Langerhans' cell histiocytosis of the temporal bone in pediatric patients: imaging and follow-up. AJR Am J Roentgenol 2000; 174:217-21.
19. Woo KI, Harris GJ. Eosinophilic granuloma of the orbit: understanding the paradox of aggressive destruction responsive to minimal intervention. Ophthal Plast Reconstr Surg 2003; 19:429-39.
20. Munn SE, Olliver L, Broadbent V, Pritchard J. Use of indomethacin in Langerhans cell histiocytosis. Med Pediatr Oncol 1999; 32:247-9.
21. Brown RE. Bisphosphonates as antialveolar macrophage therapy in pulmonary Langerhans cell histiocytosis? Med Pediatr Oncol 2001; 36:641-3.
22. Farran RP, Zaretski E, Egeler RM. Treatment of Langerhans cell histiocytosis with pamidronate. J Pediatr Hematol Oncol 2001; 23:54-6.
23. Kamizono J, Okada Y, Shirahata A, Tanaka Y. Bisphosphonate induces remission of refractory osteolysis in Langerhans cell histiocytosis. J Bone Miner Res 2002; 17:1926-8.
24. Abildgaard N, Rungby J, Glerup H, Brixen K, Kassem M, Brincker H, et al. Long-term oral pamidronate treatment inhibits osteoclastic bone resorption and bone turnover without affecting osteoblastic function in multiple myeloma. Eur J Haematol 1998; 61:128-34.
25. D'Souza MJ, Oettinger CW, Shah A, Tipping PG, Huang XR, Milton GV. Macrophage depletion by albumin microencapsulated clodronate: attenuation of cytokine release in macrophage-dependent glomerulonephritis. Drug Dev Ind Pharm 1999; 25:591-6.
26. Arceci RJ, Brenner MK, Pritchard J. Controversies and new approaches to treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am 1998; 12:339-57.
27. Howarth DM, Gilchrist GS, Mullan BP, Wiseman GA, Edmonson JH, Schomberg PJ. Langerhans cell histiocytosis: diagnosis, natural history, management, and outcome. Cancer 1999; 85:2278-90.
28. Gramatovici R, D'Angio GJ. Radiation therapy in soft-tissue lesions in histiocytosis X (Langerhans' cell histiocytosis). Med Pediatr Oncol 1988; 16:259-62.
29. Dhall G, Finlay JL, Dunkel IJ, Ettinger LJ, Kellie SJ, Allen JC, et al. Analysis of outcome for patients with mass lesions of the central nervous system due to Langerhans cell histiocytosis treated with 2-chlorodeoxyadenosine. Pediatr Blood Cancer 2008; 50:72-9.
30. Imashuku S, Okazaki NA, Nakayama M, Fujita N, Fukuyama T, Koike K, et al. Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy. Pediatr Blood Cancer 2008; 50:308-11.
31. Idbaih A, Donadieu J, Barthez MA, Geissmann F, Bertrand Y, Hermine O, et al. Retinoic acid therapy in "degenerative-like" neuro-langerhans cell histiocytosis: a prospective pilot study. Pediatr Blood Cancer 2004; 43:55-8.
32. Burn DJ, Watson JD, Roddie M, Chu AC, Legg NJ, Frackowiak RS. Langerhans' cell histiocytosis and the nervous system. J Neurol 1992; 239:345-50.
33. Ottaviano F, Finlay JL. Diabetes insipidus and Langerhans cell histiocytosis: a case report of reversibility with 2-chlorodeoxyadenosine. J Pediatr Hematol Oncol 2003; 25:575-7.
34. Kaltsas GA, Powles TB, Evanson J, Plowman PN, Drinkwater JE, Jenkins PJ, et al. Hypothalamo-pituitary abnormalities in adult patients with langerhans cell histiocytosis: clinical, endocrinological, and radiological features and response to treatment. J Clin Endocrinol Metab 2000; 85:1370-6.
35. Basset F, Corrin B, Spencer H, Lacronique J, Roth C, Soler P, et al. Pulmonary histiocytosis X. Am Rev Respir Dis 1978; 118:811-20.
36. Friedman PJ, Liebow AA, Sokoloff J. Eosinophilic granuloma of lung. Clinical aspects of primary histiocytosis in the adult. Medicine 1981; 60:385-96.
37. Colby TV, Lombard C. Histiocytosis X in the lung. Hum Pathol 1983; 14:847-56.
38. Schonfeld N, Frank W, Wenig S, Uhrmeister P, Allica E, Preussler H, et al. Clinical and radiologic features, lung function and therapeutic results in pulmonary histiocytosis X. Respiration 1993; 60:38-44.
39. Travis WD, Borok Z, Roum JH, Zhang J, Feuerstein I, Ferrans VJ, et al. Pulmonary Langerhans cell granulomatosis (histiocytosis X). A clinicopathologic study of 48 cases. Am J Surg Pathol 1993; 17:971-86.
40. Delobbe A, Durieu J, Duhamel A, Wallaert B. Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X). Groupe d'Etude en Pathologie Interstitielle de la Societe de Pathologie Thoracique du Nord. Eur Respir J 1996; 9:2002-6.
41. Crausman RS, Jennings CA, Tuder RM, Ackerson LM, Irvin CG, King TE Jr. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. Am J Respir Crit Care Med 1996; 153:426-35.
42. Hance AJ, Basset F, Saumon G, Danel C, Valeyre D, Battesti JP, et al. Smoking and interstitial lung disease. The effect of cigarette smoking on the incidence of pulmonary histiocytosis X and sarcoidosis. Ann N Y Acad Sci 1986; 465:643-56.
43. Aguayo SM, Kane MA, King TE Jr., Schwarz MI, Grauer L, Miller YE. Increased levels of bombesin-like peptides in the lower respiratory tract of asymptomatic cigarette smokers. J Clin Invest 1989; 84:1105-13.
44. Youkeles LH, Grizzanti JN, Liao Z, Chang CJ, Rosenstreich DL. Decreased tobacco-glycoproteininduced lymphocyte proliferation in vitro in pulmonary eosinophilic granuloma. Am J Respir Crit Care Med 1995; 151:145-50.
45. Francus T, Klein RF, Staiano-Coico L, Becker CG, Siskind GW. Effects of tobacco glycoprotein (TGP) on the immune system. II. TGP stimulates the proliferation of human T cells and the differentiation of human B cells into Ig secreting cells. J Immunol 1988; 140:1823-9.
46. King TE Jr., Schwarz MI, Dreisin RE, Pratt DS, Theofilopoulos AN. Circulating immune complexes in pulmonary eosinophilic granuloma. Ann Intern Med 1979; 91:397-9.
47. Mogulkoc N, Veral A, Bishop PW, Bayindir U, Pickering CA, Egan JJ. Pulmonary Langerhans' cell histiocytosis: radiologic resolution following smoking cessation. Chest 1999; 115:1452-5.
48. Morimoto T, Matsumura T, Kitaichi M. [Rapid remission of pulmonary eosinophilic granuloma in a young male patient after cessation of smoking]. Nihon Kokyuki Gakkai Zasshi 1999; 37:140-5.
49. Von Essen S, West W, Sitorius M, Rennard SI. Complete resolution of roentgenographic changes in a patient with pulmonary histiocytosis X. Chest 1990; 98:765-7.
50. Dauriat G, Mal H, Thabut G, Mornex JF, Bertocchi M, Tronc F, et al. Lung transplantation for pulmonary Langerhans' cell histiocytosis: a multicenter analysis. Transplantation 2006; 81:746-50.
51. Ceci A, de Terlizzi M, Colella R, Loiacono G, Balducci D, Surico G, et al. Langerhans cell histiocytosis in childhood: results from the Italian Cooperative AIEOP-CNR-H.X '83 study. Med Pediatr Oncol 1993; 21:259-64.
52. Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol 1994; 23:72-80.
53. Ladisch S, Gadner H, Arico M, Broadbent V, Grois N, Jacobson A, et al. LCH-I: a randomized trial of etoposide vs. vinblastine in disseminated Langerhans cell histiocytosis. The Histiocyte Society. Med Pediatr Oncol 1994; 23:107-10.
54. Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr 2001; 138:728-34.
55. Gadner H, Grois N, Potschger U, Minkov M, Arico M, Braier J, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008; 111:2556-62.
56. Imamura T, Sato T, Shiota Y, Kanegane H, Kudo K, Nakagawa S, et al. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan. Int J Hematol 2010; 91:646-51.
57. Saven A, Burian C. Cladribine activity in adult langerhans-cell histiocytosis. Blood 1999; 93:4125-30.
58. Grau J, Ribera JM, Tormo M, Indiano JM, Vercher J, Sandoval V, et al. Results of treatment with 2-chlorodeoxyadenosine in refractory or relapsed Langerhans cell histiocytosis. Study of 9 patients. Med Clin 2001; 116:339-42.
59. Pardanani A, Phyliky RL, Li CY, Tefferi A. 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. Mayo Clin Proc 2003; 78:301-6.
60. Mottl H, Stary J, Chanova M, Nekolna M, Drahokoupilova E, Smelhaus V. Treatment of recurrent Langerhans cell histiocytosis in children with 2-chlorodeoxyadenosine. Leuk Lymphoma 2006; 47:1881-4.
61. Saven A, Foon KA, Piro LD. 2-Chlorodeoxyadenosineinduced complete remissions in Langerhans-cell histiocytosis. Ann Intern Med 1994; 121:430-2.
62. Bernard F, Thomas C, Bertrand Y, Munzer M, Landman Parker J, Ouache M, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005; 41:2682-9.
63. Rodriguez-Galindo C, Jeng M, Khuu P, McCarville MB, Jeha S. Clofarabine in refractory Langerhans cell histiocytosis. Pediatr Blood Cancer 2008; 51:703-6.
64. McClain KL, Kozinetz CA. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer 2007; 48:44-9.
65. Henter JI, Karlen J, Calming U, Bernstrand C, Andersson U, Fadeel B. Successful treatment of Langerhans'-cell histiocytosis with etanercept. N Engl J Med 2001; 345:1577-8.
66. Cardoso JC, Cravo M, Cardoso R, Brites MM, Reis JP, Tellechea O, et al. Langerhans cell histiocytosis in an adult: good response of cutaneous lesions to acitretin. Clin Exp Dermatol 2010; 35:627-30.
67. Derenzini E, Fina MP, Stefoni V, Pellegrini C, Venturini F, Broccoli A, et al. MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. Ann Oncol 2010; 21:1173-8.
68. Nakajima K, Morisawa R, Kodama H, Sano S. Successful treatment with cyclophosphamide of Langerhans cell histiocytosis involving the skin and lymph nodes in an adult patient. Clin Exp Dermatol 2010; 35:791-2.